New antibody combo targets Hard-to-Treat cancers
Disease control
Recruiting now
This early-stage trial is testing a new drug called PRTH-101, alone or with an existing immunotherapy (pembrolizumab), in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The study will enroll about 270 people and focus on safety, do…
Phase: PHASE1 • Sponsor: Incendia Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC